Xylem Q2 revenue rises 2% to $2.3 billion; EPS up 19%, full-year EPS outlook raised
Xylem reported second-quarter 2026 revenue of $2.3 billion, up 2% on a reported basis, and net income attributable to Xylem of $263 million, or $1.11 per share, up 19%. The company raised its full-year adjusted EPS guidance to $5.55 to $5.70 from $5.35 to $5.60, but lowered its full-year revenue growth forecast to about 2% from 2% to 3%.
Key points
- Q2 2026 adjusted EPS was $1.46, up 16%; orders were $3.1 billion, up 42% on a reported basis
- Full-year 2026 adjusted EPS guidance raised to $5.55 to $5.70 from $5.35 to $5.60
- Full-year 2026 revenue forecast of about $9.2 billion, up about 2% reported, versus 2% to 3% previously guided
- Q2 adjusted EBITDA margin was 23.3%, up 150 basis points year over year
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.